Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

188

Participants

Timeline

Start Date

October 14, 2025

Primary Completion Date

August 1, 2027

Study Completion Date

April 27, 2028

Conditions

Hidradenitis Suppurativa

Interventions

DRUG

Brivekimig

"* Pharmaceutical form: Solution for injection in vial~* Route of administration: Subcutaneous injection"

DRUG

Placebo

"* Pharmaceutical form: Solution for injection in vial~* Route of administration: Subcutaneous injection"